ENSEM - About the company
ENSEM is a series A company based in Boston (United States), founded in 2021 by Sean Wuxiong Cao. It operates as a Developer of transformative therapies for the treatment of cancer. ENSEM has raised $67M in funding from Notable Capital. The company has 3422 active competitors, including 1129 funded and 787 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.
Company Details
Developer of transformative therapies for the treatment of cancer. The company leverages the Kinetic Ensemble platform that integrates computational and AI deep learning methodologies to develop small molecule precision medicines for oncology indications.
- Website
- ensemtx.com
- Email ID
- *****@ensemtx.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2021
Location
Boston, United States
Stage
Series A
Total Funding
$67M in 1 round
Latest Funding Round
Investors
Ranked
208th among 3422 active competitors
Employee Count
19 as on Sep 30, 2026
Similar Companies
Sign up to download ENSEM's company profile
ENSEM's funding and investors
ENSEM has raised a total funding of $67M over 1 round. Its latest funding round was a Series A round on Apr 06, 2022 for $*****. 5 investors participated in its latest round. ENSEM has 5 institutional investors.
Here is the list of recent funding rounds of ENSEM:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 06, 2022 | 3874588 | Series A | 8426281 | 1825585 | 7551094 | 1514123 |
Access funding benchmarks and valuations. Sign up today!View details of ENSEM's funding rounds and investors
ENSEM's founders and board of directors
Founder? Claim ProfileThe founders of ENSEM is Sean Wuxiong Cao.
Here are the details of ENSEM's key team members:
- Sean Wuxiong Cao: Former Co-Founder & CEO of ENSEM.
View details of ENSEM's Founder profiles and Board Members
ENSEM's employee count trend
ENSEM has 19 employees as of Sep 26. Here is ENSEM's employee count trend over the years:
Uncover ENSEM's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ENSEM's Competitors and alternates
Top competitors of ENSEM include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of ENSEM, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 77/100 | |
3rd | Kite Pharma 2009, Los Angeles (United States), Acquired | Developer of cancer immunotherapy products using genetic engineering | $97.7M | 76/100 | |
4th |  Attovia 2023, Fremont (United States), Public | Developer of antibody-based therapeutics for immune-mediated diseases and oncology | $255M | 72/100 | |
5th |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 72/100 | |
6th |  Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 72/100 | |
7th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
8th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 71/100 | ||
9th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
10th |  Strand Therapeutics 2017, Cambridge (United States), Series B | Provider of platform to deliver mRNA therapeutics for multi functional treatments | $256M | 71/100 | |
208th |  ENSEM 2021, Boston (United States), Series A | Developer of transformative therapies for the treatment of cancer | $67M | 58/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on ENSEM's competitors? Click here to see the top ones
ENSEM's Investments and acquisitions
ENSEM has made no investments or acquisitions yet.
Reports related to ENSEM
Here is the latest report on ENSEM's sector:
News related to ENSEM
Media has covered ENSEM for 1 event in last 1 year, It was about company updates.
•
Ensem Therapeutics Highlights Novel, Potent, and Selective Oral pan-KRAS and WRN Inhibitors with Best-in-Class PotentialBusiness Wire•Apr 17, 2026•ENSEM
•
Ensem Therapeutics Announces U.S. FDA IND Clearance to Initiate Clinical Development of ETX-636Business Wire•Apr 22, 2025•ENSEM
•
•
•
BeiGene licenses CDK2 inhibitor from Ensem in potential $1.33B dealEndPoints News•Nov 21, 2023•BeiGene, ENSEM, Blueprint Medicines, Incyte and 1 other
•
Ensem Therapeutics and Alibaba Cloud Reach Comprehensive Cooperation36Kr•May 27, 2023•ENSEM, Alibaba Cloud
•
Ensem Therapeutics Raised $67M in Series B FinancingApr 09, 2022•ENSEM, Notable Capital, Pavilion Capital Partners, Cenova and 3 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about ENSEM
Explore our recently published companies
- Tibnology - India based, Unfunded company
- SS Concrete Coatings - Freeport based, Unfunded company
- S K Reality - Pune based, Unfunded company
- Roemo Fliesen - Germany based, 1991 founded, Unfunded company
- Rocky Mountain Trades - Logan based, Unfunded company
- Roberta Flanagan Realtor - Merced based, 1960 founded, Unfunded company
